Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing...
Cancer
AIxMed and CorePlus Partner to Demonstrate a Digital Urine Cytology Workflow Solution
AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics. SANTA CLARA, Calif., May 30,...
Provider Network Holdings Appoints Dr. Edith A. Perez, M.D. as Chief Medical Officer of Cornerstone Specialty Network
PEARLAND, Texas, May 30, 2025 /PRNewswire/ -- Cornerstone Specialty Network ("Cornerstone"), a leading provider of innovative solutions for specialty providers...
Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer
NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater...
AIxMed Partnership with Lumea Enhances Digital Pathology Platform with AI-Powered Urine Cytology Solution
Lumea and AIxMed team up to bring AI driven urine cytology to Lumea's platform, targeting improved bladder cancer diagnostics. SANTA...
Real-World Deployments Signal AI Healthcare Is Ready for Scale
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 30, 2025 /PRNewswire/ -- The concept...
Velsera Powers the Knowledgebase Behind Illumina’s TSO Comprehensive Test, Now Approved in Japan
BOSTON, May 30, 2025 /PRNewswire/ -- Velsera announces that its clinical Knowledgebase is powering the interpretation framework behind Illumina's TruSight™ Oncology...
Ontada Unveils Comprehensive Data on Social Determinants of Health and Outcomes of Early-Onset Colorectal Cancer at ASCO
Findings show Black and Hispanic Patients Have 30% Higher Risk of Advanced-Stage DiagnosisBOSTON--(BUSINESS WIRE)--Ontada®, a leader in real-world oncology data...
Ontada Unveils Comprehensive Data on Social Determinants of Health and Outcomes of Early-Onset Colorectal Cancer at ASCO
Findings show Black and Hispanic Patients Have 30% Higher Risk of Advanced-Stage DiagnosisBOSTON--(BUSINESS WIRE)--Ontada®, a leader in real-world oncology data...
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 2030
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain...
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 2030
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain...
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1,...
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing...
Shareholder Update
May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage...
Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer
SYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for...
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq:...
Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence...
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology...
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 30, 2025...
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of lifeRESEARCH TRIANGLE...